ArticleAnnals of laboratory medicine2022
Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used.
Article in Annals of laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- OptimizedJournal of veterinary science · 2026Article
- Article
- Optimization of Natural Killer Cell Expansion with K562-mbIL-18/-21 Feeder Cells and Assurance of Feeder Cell-free Products.Annals of laboratory medicine · 2026Article
- Impact of CPPs on primary human NK cell CQAs during cell expansion - an experimental study using design of experiments.Frontiers in bioengineering and biotechnology · 2026Article
- iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.Frontiers in immunology · 2026Review
- The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances.Biomedicines · 2025Review
- Synthetic short mRNA prevents metastasis via innate-adaptive immunity.Nature communications · 2025Article
- Nanomaterial assisted natural killer cell therapy.Frontiers in immunology · 2025Review
- Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.Frontiers in immunology · 2025Article
- Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.Nature reviews. Clinical oncology · 2025Review
- Recent advances in feeder-free NK cell expansion as a future direction of adoptive cell therapy.Frontiers in immunology · 2025Review
- Influenza-specific antibody-mediated and complement-dependent cellular cytotoxicity-inducing antibodies in vaccinated and infected pigs.Frontiers in immunology · 2025Article
- A Critical Role of Culture Medium Selection in Maximizing the Purity and Expansion of Natural Killer Cells.Cells · 2024Article
- Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.Annals of laboratory medicine · 2024Review
- Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.Scientific reports · 2024Article
- Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells.Scientific reports · 2023Article
- Suitability of EDTA-anticoagulated Blood for Natural Killer Cell Activity Testing Using Flow Cytometry.Annals of laboratory medicine · 2023Article
- Ex Vivo Expansion of Highly Cytotoxic Natural Killer Cells Using Optimal Culture Medium.Annals of laboratory medicine · 2022Article
- Multifaceted characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and placental blood.Cancer cell international · 2022Article
- Selective Expansion of NKG2C+ Adaptive NK Cells Using K562 Cells Expressing HLA-E.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adoptive cell therapy using umbilical cord blood (UCB)-derived allogeneic natural killer (NK) cells has shown encouraging results. However, because of the insufficient availability of NK cells and limited UCB volume, more effective culture methods are required. NK cell expansion and functionality are largely affected by the culture medium. While human serum is a major affecting component in culture media, the way it regulates NK cell functionality remains elusive. We elucidated the effects of different culture media and human serum supplementation on UCB NK cell expansion and functionality. Methods: UCB NK cells were cultured under stimulation with K562-OX40L-mbIL-18/21 feeder cells and IL-2 and IL-15 in serum-containing and serum-free culture media. The effects of the culture media and human serum supplementation on NK cell expansion and cytotoxicity were evaluated by analyzing the expansion rate, activating and inhibitory receptor levels, and the cytotoxicity of the UCB NK cells. Results: The optimal medium for NK cell expansion was Dulbecco's modified Eagle's medium/Ham's F12 with supplements and that for cytotoxicity was AIM V supplemented with Immune Cell Serum Replacement. Shifting media is an advantageous strategy for obtaining several highly functional UCB NK cells. Live cell imaging and killing time measurement revealed that human serum enhanced NK cell proliferation but delayed target recognition, resulting in reduced cytotoxicity. Conclusions: Culture medium supplementation with human serum strongly affects UCB NK cell expansion and functionality. Thus, culture media should be carefully selected to ensure both NK cell quantity and quality for adoptive cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.